Article

You have free access to this content

Fed-batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty

  1. James Pollock1,
  2. Sa V. Ho2,
  3. Suzanne S. Farid1,*

Article first published online: 6 AUG 2012

DOI: 10.1002/bit.24608

Issue

Biotechnology and Bioengineering

Biotechnology and Bioengineering

Volume 110, Issue 1, pages 206–219, January 2013

Additional Information

How to Cite

Pollock, J., Ho, S. V. and Farid, S. S. (2013), Fed-batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty. Biotechnol. Bioeng., 110: 206–219. doi: 10.1002/bit.24608

Author Information

  1. 1

    Department of Biochemical Engineering, The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK; telephone: 44-20-7679-4415; fax: +44 20 7916 3943

  2. 2

    Pfizer R&D Global Biologics, 700 Chesterfield Parkway, BB3D, Chesterfield, MO 63017

*Department of Biochemical Engineering, The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK; telephone: 44-20-7679-4415; fax: +44 20 7916 3943

Publication History

  1. Issue published online: 20 NOV 2012
  2. Article first published online: 6 AUG 2012
  3. Accepted manuscript online: 13 JUL 2012 08:34AM EST
  4. Manuscript Revised: 5 JUL 2012
  5. Manuscript Accepted: 5 JUL 2012
  6. Manuscript Received: 2 APR 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (949K)

References

  • Bosch P, Lundgren B, Kaisermayer C. 2008. How to construct a monoclonal antibody factory: A comparison of production costs in fed batch and perfusion culture with microcarriers—Part two. Bioprocess J 7(2): 30–43.
  • Cacciuttolo M. 2007. Perfusion or fed-batch? A matter of perspective. In: Butler M, editor. Cell culture and upstream processing. London, UK: Taylor Francis Group. p 173–184.
  • Carstens JN, Clarke HRG, Jensen JP. 2009. Perfusion! Jeopardy or the ultimate advantage? Bioprocess Int Webinar, October.
  • Centocor ILA. 2006. http://www.epa.ie/licences/lic_eDMS/090151b2800c1411.pdf (accessed 2011).
  • Crowley J, Wubben M, Coco Martin JM. 2008. Process for cell culturing by continuous perfuison and alternating tangential flow patent 20080131934.
  • Deb K. 2008. Multi-objective optimization using evolutionary algorithms. New Jersey: John Wiley & Sons, Ltd.
  • Deo YM, Mahadevan MD, Fuchs R. 1996. Practical considerations in operation and scale-up of spin-filter based bioreactors for monoclonal antibody production. Biotechnol Prog 12(1): 57–64.
    Direct Link:
  • Farid SS. 2006. Established bioprocesses for producing antibodies as a basis for future planning. Cell Cult Eng 101: 1–42.
  • Farid SS. 2007. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Anal Technol Biomed Life Sci 848(1): 8–18.
  • Farid SS. 2009a. Economic drivers and trade-offs in antibody purification processes. Bio Pharm Int S38–S42.
  • Farid SS. 2009b. Process economics drivers in industrial monoclonal antibody manufacture. In: Gottschalk U, editor. Process scale purification of antibodies. New Jersey: John Wiley & Sons, Inc. p 239–262.
  • Farid SS, Novais JL, Karri S, Washbrook J, Titchener-Hooker NJ. 2000. A tool for modeling strategic decisions in cell culture manufacturing. Biotechnol Prog 16(5): 829–836.
    Direct Link:
  • Farid SS, Washbrook J, Titchener-Hooker NJ. 2005. Decision-support tool for assessing biomanufacturing strategies under uncertainty: Stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol Prog 21(2): 486–497.
    Direct Link:
  • Farid SS, Washbrook J, Titchener-Hooker NJ. 2007. Modelling biopharmaceutical manufacture: Design and implementation of SimBiopharma. Comput Chem Eng 31(9): 1141–1158.
  • Ho SV, McLaughlin JM, Pollock J, Farid SS. 2011. Toward Greener therapeutic proteins. In: Tao J, Kazlazuskas R, editors. Biocatalysis for Grenn Chemistry and Chemical Process Development. New Jersey: John Wiley & Sons. p 197–219.
  • Hwang CL, Yoon K. 1981. Multiple attribute decision making—Methods and applications. A state-of-the-art survey. lecture notes in economics and mathmatical systems. Berlin, Heidelberg, New York: Springer Verlag.
  • Kelley B. 2009. Industrialization of mAb production technology. The bioprocessing industry at a crossroads. Mabs 1(5): 443–452.
  • Kelley BD. 2007. Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnol Prog 23(5): 995–1008.
  • Lim AC, Washbrook J, Titchener-Hooker NJ, Farid SS. 2006. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol Bioeng 93(4): 687–697.
    Direct Link:
  • Lim AC, Zhou YH, Washbrook J, Sinclair A, Fish B, Francis R, Titchener-Hooker NJ, Farid SS. 2005. Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty. Biotechnol Prog 21(4): 1231–1242.
    Direct Link:
  • Liu HF, Ma J, Winter C, Bayer R. 2010. Recovery and purification process development for monoclonal antibody production. Mabs 2: 5.
  • Novais JL, Titchener-Hooker NJ, Hoare M. 2001. Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnology Bioeng 75(2): 143–153.
    Direct Link:
  • Paz A, Puich M. 2004. Simulations improve produciton capacity. BioPharm Int, May.
  • Rodrigues ME, Costa AR, Henriques M, Azeredo J, Oliveira R. 2010. Technological progresses in monoclonal antibody production systems. Biotechnol Prog 26(2): 332–351.
  • Shanklin T, Roper K, Yegneswaran PK, Marten MR. 2001. Selection of bioprocess simulation software for industrial applications. Biotechnol Bioeng 72(4): 483–489.
    Direct Link:
  • Sheldon RA. 2007. The E factor: Fifteen years on. Green Chem 9(12): 1273–1283.
  • Shevitz J. 2000. Fluid filtration system patent 6544424.
  • Stonier A, Smith M, Hutchinson N, Farid SS. 2009. Dynamic simulation framework for design of lean biopharmaceutical manufacturing operations. Computer-Aided Chemical Engineering Series; 2009. Amesterdam: Elsevier B. V. Ltd. p 1069–1074.
  • Triantaphyllou E. 2000. Multi-criteria decision making methods: A comparative study. Netherlands: Kluwer Acadmic Publishers.
  • Vallez-Chetreanu F, Ferreira LGF, Rabe R, von Stockar U, Marison IW. 2007. An on-line method for the reduction of fouling of spin-filters for animal cell perfusion cultures. J Biotechnol 130(3): 265–273.
  • Voisard D, Meuwly F, Ruffieux PA, Baer G, Kadouri A. 2003. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng 82(7): 751–765.
    Direct Link:
  • Wojciechowski PW, Smit HI, Myers MM, Voronko PJ, Laverty T, Ramelmeier RA, Siegel RC. 2007. Making changes to a biopharmaceutical process during development and commercial manufacturing: The REMICADE story. In: Shukla AA, Etzel MR, Gadam S, editors. Process scale bioseperations for the biophamceutical industry. London, UK: Taylor Francis Group. p 507–523.
  • Yabannavar VM, Singh V, Connelly NV. 1992. Mammalian cell retention in a spinfilter perfusion bioreactor. Biotechnol Bioeng 40(8): 925–933.
    Direct Link:
View Full Article (HTML) Get PDF (949K)